ClinicalTrials.gg
RecruitingNCT06713889Bio-TAVIUpdated May 27, 2026

Identifying Biological Markers of Cardiovascular Events in Patients With Aortic Stenosis or TAVI

An observational study in Aortic Stenosis, sponsored by Hospices Civils de Lyon. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Aortic Valve Stenosis with a site in France — 22 open to participants now, 34 under way, 2 of them phase 3. Aortic Valve Stenosis · France.

Planned enrollment
53rd of 62
125 · median 470
Started
2024
with 6 others
Observational
62 of 131
10 open now
Primary completion
2029-06
later than 31 of 33 live
Registered
125th of 131
by date
Lead sponsor
4 of 131
Hospices Civils de Lyon

Among the 131 studies in Aortic Valve Stenosis with a site in France, this one is the 53rd largest by planned enrollment of the 62 observational ones that give a count, is one of 7 that started in 2024, is one of 62 observational ones, reaches primary completion later than 31 of the 33 other live ones, and was the 125th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

22 of the 131 studies in Aortic Valve Stenosis with a site in France are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Aortic Valve Stenosis with a site in France, or all of them as a file.
02

Study summary

Aortic stenosis, a common cardiovascular disease, is pathophysiologically associated with a chronic inflammatory myocardial reaction and fibrosis leading to cardiac dysfunction and impaired coronary perfusion. These elements may precede the onset of symptoms. The assessment of inflammatory and fibrosis factors (in particular by means of biomarkers) in patients with aortic stenosis will make it possible to identify asymptomatic patients at greater risk who could benefit from intervention earlier. This is part of a personalised medicine adapted to the patient.

Patients will be recruited during their TAVI (Transcatheter Aortic Valve Implantation) assessment consultation. If the patient agrees to take part in the study, information relating to routine care procedures will be collected (patient history, clinical examinations, electrocardiogram, echography, coronary angiography, TAVI procedure if applicable, biology).

Outside of routine care, a biocollection will be established (serum, plasma), quality of life questionnaires will be carried out and adverse events will be collected where present.

Patients will be divided into 3 groups according to the indication for TAVI (Group A - symptomatic severe aortic stenosis with indication for TAVI, Group B - asymptomatic severe aortic stenosis without indication for TAVI, Group C - asymptomatic moderate aortic stenosis without indication for TAVI).

The main objective is to compare the levels of biomarkers of inflammation and fibrosis between the 3 groups at each sampling time common to all three groups between inclusion and 1-year follow-up.

03

Conditions studied

  • Aortic Stenosis

Keywords

  • Aortic stenosis
  • TAVI
  • Cardiology
  • Biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

125 patients will be selected from among those seen in consultation for aortic stenosis assessment in the cardiology departments of the Louis Pradel and Croix-Rousse hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients >=18 years of age
  • Patient with symptomatic or asymptomatic severe or moderately severe aortic stenosis (according to the recommendations of the European Society of Cardiology - ESC).
  • No opposition.

Exclusion criteria

Exclusion Criteria:

  • Conjunctive heart disease (e.g. amyloidosis).
  • Presence of a to TAVI.
  • Impossibility of giving the subject informed information.
  • Privation of civil rights (curatorship, tutorship, protection of justice).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group A

    Patients with symptomatic severe aortic stenosis, with indication for TAVI. They are followed at inclusion, during hospitalisation of the TAVI procedure, at 1-month follow-up, at 1-year follow-up and by phone at 2 years follow-up.

    Biological: Biocollection · Behavioral: Quality of life questionnaires

  • Group B

    Patients with asymptomatic severe aortic stenosis, without indication for TAVI. They are followed at inclusion, at 1-month follow-up, at 1-year follow-up and at 2 years follow-up.

    Biological: Biocollection · Behavioral: Quality of life questionnaires

  • Group C

    Patients with asymptomatic middle aortic stenosis, without indication for TAVI. They are followed at inclusion, at 1-month follow-up, at 1-year follow-up and at 2 years follow-up.

    Biological: Biocollection · Behavioral: Quality of life questionnaires

Interventions

  • BiologicalBiocollection

    At each sampling time, 2 dry tubes of 4 ml, 1 EDTA tube of 4 ml, and 1 heparinised tube of 4 ml, i.e. a total of 16 ml per sampling time. Group A patients will be sampled at inclusion (or before the TAVI procedure), during and after the TAVI procedure, at 1 month follow-up and at 1 year follow-up, for a total of 120 ml. Patients in groups B and C will be sampled at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up, for a total of 80 ml.

  • BehavioralQuality of life questionnaires

    EQ-5D-5L and HAD questionnaire at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up

06

What researchers measure

Primary outcomes

  1. Comparing biomarkers

    The primary endpoint is the level of biomarkers of inflammation and fibrosis in the 3 groups of patients.

    Time frame: At V0 (inclusion), V4 (1-month follow up) and V5 (1-year follow up).

07

Study locations

2 of 2 sites recruiting
  • Hospices Civils de Lyon - Hôpital Croix Rousse
    Lyon, 69004, France
    Recruiting
  • Hospices Civils de Lyon - Hôpital Louis Pradel
    Lyon, 69500, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jun 2029, 54 months after the start.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 54 months is above that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 3, 2024
StartActual
Dec 19, 2024
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2030
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06713889
Responsible party
Sponsor
First posted
Dec 3, 2024
Start date
Dec 19, 2024
Primary completion
Jun 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
May 27, 2026

Study contacts

Ahmad HAYEK, MD
Contact
ahmad.hayek@chu-lyon.fr
4 72 35 72 80 ext. +33
Yvonne VARILLON
Contact
yvonne.varillon@chu-lyon.fr
4 72 35 69 64 ext. +33
Ahmad HAYEK, MD
principal investigator · Plateau technique interventionnel - Hôpital Louis Pradel, GHE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion